Treatment of chronic myelogenous leukemia with interferon alfa-2c: response rate and toxicity in a phase II multicenter study. The Austrian Biological Response Modifier (BRM) Study Group.
Thaler
J
J
Department of Internal Medicine, University of Innsbruck, Austria.
Gastl
G
G
Fluckinger
T
T
Niederwieser
D
D
Huber
H
H
Seewann
H
H
Silly
H
H
Lang
A
A
Abbrederis
C
C
Gadner
H
H
D000293:Adolescent; D000328:Adult; D000368:Aged; D002869:Chromosome Aberrations; D025063:Chromosome Disorders; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000628:therapy*; D008875:Middle Aged; D011994:Recombinant Proteins
D007370:Interferon Type I; D011994:Recombinant Proteins